(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $19.52
発行日: 15 2月 2024 @ 04:28
リターン: -18.47%
前回のシグナル: 2月 15 - 01:53
前回のシグナル:
リターン: 2.55 %
Live Chart Being Loaded With Signals
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong...
Stats | |
---|---|
本日の出来高 | 362 617 |
平均出来高 | 639 958 |
時価総額 | 1.57B |
EPS | $0 ( 2024-02-27 ) |
次の収益日 | ( $-0.930 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.55 |
ATR14 | $0.0180 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Smiley Joshua L | Buy | 7 145 | American Depositary Shares |
2024-04-04 | Smiley Joshua L | Sell | 1 988 | American Depositary Shares |
2024-04-03 | Smiley Joshua L | Sell | 7 145 | Restricted Share Units |
2024-04-03 | Reinhart Harald | Buy | 5 270 | American Depositary Shares |
2024-04-04 | Reinhart Harald | Sell | 2 105 | American Depositary Shares |
INSIDER POWER |
---|
72.37 |
Last 100 transactions |
Buy: 2 027 943 | Sell: 363 897 |
ボリューム 相関
Zai Lab Ltd 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Zai Lab Ltd 相関 - 通貨/商品
Zai Lab Ltd 財務諸表
Annual | 2023 |
収益: | $266.72M |
総利益: | $170.90M (64.08 %) |
EPS: | $-3.46 |
FY | 2023 |
収益: | $266.72M |
総利益: | $170.90M (64.08 %) |
EPS: | $-3.46 |
FY | 2022 |
収益: | $215.04M |
総利益: | $141.02M (65.58 %) |
EPS: | $-5.03 |
FY | 2021 |
収益: | $144.31M |
総利益: | $92.07M (63.80 %) |
EPS: | $-9.07 |
Financial Reports:
No articles found.
Zai Lab Ltd
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。